NORDEN
3.3.2021 15:31:55 CET | Globenewswire | Press release
ANNOUNCEMENT NO. 55 - 3 MARCH 2021
The employees of Dampskibsselskabet NORDEN A/S have elected the following employee representatives and alternates for the Company’s Board of Directors for a 3-year period:
Employee representatives:
Benedicte Hedengran Wegener, Head of Operations, Asset Management (newly elected)
Christina Lerchedahl, Business Application Specialist (newly elected)
Henrik Røjel, Head of Fuel Efficiency and Decarbonisation (newly elected)
Alternates:
Stine Maria Gøttrup, Chartering Manager
William Boatwright, Senior Manager
Arthur Gaidon, Senior FFA Trader
The new employee representatives will join the Board of Directors immediately following the annual general meeting on Thursday 25 March 2020.
The present employee representatives Jesper Svenstrup will withdraw from the Board of Directors immediately following the annual general meeting on 25 March 2020.
Kind regards,
Dampskibsselskabet NORDEN A/S
Martin Badsted
CFO
For further information:
Martin Badsted, CFO, tel.: +45 3315 0451
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
